Should we treat children with idiopathic short stature? Workshop held in St.-Paul-de-Vence, France, April 18-19, 1999

C. J.H. Kelnar; K. Albertsson-Wikland; R. L. Hintz; M. B. Ranke; R. G. Rosenfeld

Should we treat children with idiopathic short stature? Workshop held in St.-Paul-de-Vence, France, April 18-19, 1999

C. J.H. Kelnar, K. Albertsson-Wikland, R. L. Hintz, M. B. Ranke, R. G. Rosenfeld

Pediatrics

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

The use of growth hormone (GH) to treat short children who are clearly GH-deficient is now well accepted. However, GH treatment of short children who have no currently recognizable abnormalities in their GH-insulin-like growth factor I axis remains controversial. Whether such children with so-called idiopathic short stature (ISS) should be treated with GH was the subject of an international workshop held in St.-Paul-de-Vence, France, in April 1999. This article summarizes the issues discussed at the workshop, including the definition of ISS, ethical and health-economic aspects of treatment, results from clinical trials and surveillance studies, and the use of prediction models in aiding treatment decisions. Copyright (C) 2000 S. Karger AG, Basel.

Original language	English (US)
Pages (from-to)	150-157
Number of pages	8
Journal	Hormone Research
Volume	52
Issue number	3
State	Published - Dec 1 1999

Keywords

Growth
Growth hormone
Height, final
Prediction model, height
Quality of life
Short stature, idiopathic

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Cite this

@article{cae24b39da9548aba7290604687ae5b0,

title = "Should we treat children with idiopathic short stature? Workshop held in St.-Paul-de-Vence, France, April 18-19, 1999",

abstract = "The use of growth hormone (GH) to treat short children who are clearly GH-deficient is now well accepted. However, GH treatment of short children who have no currently recognizable abnormalities in their GH-insulin-like growth factor I axis remains controversial. Whether such children with so-called idiopathic short stature (ISS) should be treated with GH was the subject of an international workshop held in St.-Paul-de-Vence, France, in April 1999. This article summarizes the issues discussed at the workshop, including the definition of ISS, ethical and health-economic aspects of treatment, results from clinical trials and surveillance studies, and the use of prediction models in aiding treatment decisions. Copyright (C) 2000 S. Karger AG, Basel.",

keywords = "Growth, Growth hormone, Height, final, Prediction model, height, Quality of life, Short stature, idiopathic",

author = "Kelnar, {C. J.H.} and K. Albertsson-Wikland and Hintz, {R. L.} and Ranke, {M. B.} and Rosenfeld, {R. G.}",

year = "1999",

month = dec,

day = "1",

language = "English (US)",

volume = "52",

pages = "150--157",

journal = "Steroids and lipids research",

issn = "1663-2818",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - Should we treat children with idiopathic short stature? Workshop held in St.-Paul-de-Vence, France, April 18-19, 1999

AU - Kelnar, C. J.H.

AU - Albertsson-Wikland, K.

AU - Hintz, R. L.

AU - Ranke, M. B.

AU - Rosenfeld, R. G.

PY - 1999/12/1

Y1 - 1999/12/1

N2 - The use of growth hormone (GH) to treat short children who are clearly GH-deficient is now well accepted. However, GH treatment of short children who have no currently recognizable abnormalities in their GH-insulin-like growth factor I axis remains controversial. Whether such children with so-called idiopathic short stature (ISS) should be treated with GH was the subject of an international workshop held in St.-Paul-de-Vence, France, in April 1999. This article summarizes the issues discussed at the workshop, including the definition of ISS, ethical and health-economic aspects of treatment, results from clinical trials and surveillance studies, and the use of prediction models in aiding treatment decisions. Copyright (C) 2000 S. Karger AG, Basel.

AB - The use of growth hormone (GH) to treat short children who are clearly GH-deficient is now well accepted. However, GH treatment of short children who have no currently recognizable abnormalities in their GH-insulin-like growth factor I axis remains controversial. Whether such children with so-called idiopathic short stature (ISS) should be treated with GH was the subject of an international workshop held in St.-Paul-de-Vence, France, in April 1999. This article summarizes the issues discussed at the workshop, including the definition of ISS, ethical and health-economic aspects of treatment, results from clinical trials and surveillance studies, and the use of prediction models in aiding treatment decisions. Copyright (C) 2000 S. Karger AG, Basel.

KW - Growth

KW - Growth hormone

KW - Height, final

KW - Prediction model, height

KW - Quality of life

KW - Short stature, idiopathic

UR - http://www.scopus.com/inward/record.url?scp=0033501811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033501811&partnerID=8YFLogxK

M3 - Article

C2 - 10725780

AN - SCOPUS:0033501811

SN - 1663-2818

VL - 52

SP - 150

EP - 157

JO - Steroids and lipids research

JF - Steroids and lipids research

IS - 3

ER -

Should we treat children with idiopathic short stature? Workshop held in St.-Paul-de-Vence, France, April 18-19, 1999

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this